Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2007 5
2008 3
2009 4
2010 5
2011 5
2012 19
2013 15
2014 11
2015 18
2016 15
2017 8
2018 8
2019 6
2020 6
2021 6
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25314063

122 results

Results by year

Filters applied: . Clear all
Page 1
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P. Sinn M, et al. Eur J Cancer. 2015 Aug;51(12):1546-54. doi: 10.1016/j.ejca.2015.05.005. Epub 2015 Jun 3. Eur J Cancer. 2015. PMID: 26049689 Clinical Trial.
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M. Kurreck A, et al. Eur J Cancer. 2021 Jun;150:250-259. doi: 10.1016/j.ejca.2021.03.036. Epub 2021 Apr 30. Eur J Cancer. 2021. PMID: 33940349
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T. Nakagawa N, et al. Surgery. 2013 Apr;153(4):565-75. doi: 10.1016/j.surg.2012.10.010. Epub 2012 Dec 17. Surgery. 2013. PMID: 23253379
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.
Sinn M, Sinn BV, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler JK, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C. Sinn M, et al. Clin Cancer Res. 2020 Jul 15;26(14):3732-3739. doi: 10.1158/1078-0432.CCR-19-3034. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234756
122 results